Free accessResearch articleFirst published online 2009-11
Combined prophylactic and therapeutic intranasal vaccination against human papillomavirus type-16 using different adeno-associated virus serotype vectors
Cervical cancer is the second most frequent cancer among woman worldwide and is considered to be caused by infection with high-risk papilloma viruses. Genetic immunization using recombinant adeno-associated virus (rAAV) vectors has shown great promise for vaccination against human papillomavirus (HPV) infections.
Methods
rAAV5, -8 and -9 vectors expressing an HPV16 L1/E7 fusion gene were generated and applied intranasally for combined prophylactic and therapeutic vaccination of mice.
Results
The rAAV5 and the rAAV9 vectors showed efficient induction of both humoral and cellular immune responses, whereas rAAV8 failed to immunize mice by the intranasal route. The L1-specific immune response evoked by expression of the L1/E7 fusion gene, however, was lower than that evoked by expression of the L1 antigen alone. This deficiency could be compensated by application of Escherichia coli heat-labile enterotoxin or monophsphoryl lipid as adjuvant upon vaccination with rAAV5-L1/E7. Coimmunization of rAAV9-L1/E7 with rAAV5-L1 or boosting of rAAV9-L1/E7 with rAAV5-L1 strongly increased L1-specific neutralizing antibody titres to levels above those achieved by vaccination with vectors expressing L1 alone. Both vectors elicited a vibrant cytotoxic T-lymphocyte response against L1 or E7. Nasal immunization with rAAV5 or rAAV9 was superior to vaccination with HPV16-L1 virus-like particles (VLPs) or HPV16-L1/E7 CVLPs with respect to humoral and cellular immune responses. Vaccination with the rAAV vectors led to a significant protection of animals against a challenge with different HPV tumour cell lines.
Conclusions
Our results show that rAAV5 and rAAV9 vectors are promising candidates for a non-invasive nasal vaccination strategy.
References
1.
zur HausenH (Editor). Infections Causing Human Cancer. Weinheim: Wiley–VCH2006.
2.
StanleyM.Immunobiology of HPV and HPV vaccines.Gynecol Oncol2008; 109 Suppl 2: S15–S21.
3.
HuhW.K., RodenR.B.The future of vaccines for cervical cancer.Gynecol Oncol2008; 109: S48–S56.
4.
StanleyM., GissmannL., Nardelli-HaefigerD.Immunobiology of human papillomavirus infection and vaccination – implications for second generation vaccines.Vaccine2008; 26 Suppl 10: K62–K67.
5.
MeiselsA., MorinC (Editors). Modern Unterine Cytopathology. Chicago: ASCP Press2007.
SchaferK., MullerM., FaathS.Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection.Int J Cancer1999; 81: 881–888.
8.
OhlschlagerP., OsenW., DellK.Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice.J Virol2003; 77: 4635–4645.
9.
KaufmannA.M., NielandJ., SchinzM.HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination.Int J Cancer2001; 92: 285–293.
10.
KaufmannA.M., NielandJ.D., JochmusI.Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3).Int J Cancer2007; 121: 2794–2800.
11.
KuckD., LederC., KernA.Efficiency of HPV 16 L1/E7 DNA immunization: influence of cellular localization and capsid assembly.Vaccine2006; 24: 2952–2965.
12.
ZaissA.K., MuruveD.A.Immunity to adeno-associated virus vectors in animals and humans: a continued challenge.Gene Ther2008; 15: 808–816.
13.
SunJ.Y., Anand-JawaV., ChatterjeeS., WongK.K.Immune responses to adeno-associated virus and its recombinant vectors.Gene Ther2003; 10: 964–976.
XinK.Q., UrabeM., YangJ.A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus.Hum Gene Ther2001; 12: 1047–1061.
16.
KuckD., LauT., LeuchsB.Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1.J Virol2006; 80: 2621–2630.
17.
MouriA., NodaY., HaraH., MizoguchiH., TabiraT., NabeshimaT.Oral vaccination with a viral vector containing Aβ cDNA attenuates age-related Aβ accumulation and memory deficits without causing inflammation in a mouse Alzheimer model.FASEB J2007; 21: 2135–2148.
18.
XinK.Q., OokiT., MizukamiH.Oral administration of recombinant adeno-associated virus elicits human immunodeficiency virus-specific immune responses.Hum Gene Ther2002; 13: 1571–1581.
19.
GaoG., VandenbergheL.H., AlviraM.R.Clades of adeno-associated viruses are widely disseminated in human tissues.J Virol2004; 78: 6381–6388.
GrimmD., KayM.A., KleinschmidtJ.A.Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6.Mol Ther2003; 7: 839–850.
22.
GaoG.P., AlviraM.R., WangL., CalcedoR., JohnstonJ., WilsonJ.M.Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy.Proc Natl Acad Sci U S A2002; 99: 11854–11859.
23.
HauswirthW.W., LewinA.S., ZolotukhinS., MuzyczkaN.Production and purification of recombinant adeno-associated virus.Methods Enzymol2000; 316: 743–761.
24.
ThonesN., MullerM.Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes.Virology2007; 369: 375–388.
25.
Stahl-HennigC., EisenblatterM., JasnyE.Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques.PLoS Pathog2009; 5: e1000373.
26.
ThonesN., HerreinerA., SchadlichL., PiukoK., MullerM.A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response.J Virol2008; 82: 5472–5485.
27.
FreytagL.C., ClementsJ.D.Bacterial toxins as mucosal adjuvants.Curr Top Microbiol Immunol1999; 236: 215–236.
28.
AfioneS.A., ConradC.K., KearnsW.G.In vivo model of adeno-associated virus vector persistence and rescue.J Virol1996; 70: 3235–3241.
29.
ZabnerJ., SeilerM., WaltersR.Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer.J Virol2000; 74: 3852–3858.
30.
Liqun WangR., McLaughlinT., CossetteT.Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery.Mol Ther2009; 17: 81–87.
31.
AuricchioA., O'ConnorE., WeinerD.Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins.J Clin Invest2002; 110: 499–504.
32.
XinK.Q., MizukamiH., UrabeM.Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells.J Virol2006; 80: 11899–11910.
33.
ZincarelliC., SoltysS., RengoG., RabinowitzJ.E.Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection.Mol Ther2008; 16: 1073–1080.
34.
MullerO.J., SchinkelS., KleinschmidtJ.A., KatusH.A., BekeredjianR.Augmentation of AAV-mediated cardiac gene transfer after systemic administration in adult rats.Gene Ther2008; 15: 1558–1565.
35.
InagakiK., FuessS., StormT.A.Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8.Mol Ther2006; 14: 45–53.
36.
LimberisM.P., VandenbergheL.H., ZhangL., PicklesR.J., WilsonJ.M.Transduction efficiencies of novel AAV vectors in mouse airway epithelium in vivo and human ciliated airway epithelium in vitro.Mol Ther2009; 17: 294–301.
37.
LimberisM.P., WilsonJ.M.Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered.Proc Natl Acad Sci U S A2006; 103: 12993–12998.
38.
HalbertC.L., MillerA.D., McNamaraS.Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors.Hum Gene Ther2006; 17: 440–447.
YamamotoM., McGheeJ.R., HagiwaraY., OtakeS., KiyonoH.Genetically manipulated bacterial toxin as a new generation mucosal adjuvant.Scand J Immunol2001; 53: 211–217.
41.
AkacheB., GrimmD., PandeyK., YantS.R., XuH., KayM.A.The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9.J Virol2006; 80: 9831–9836.
42.
Di PasqualeG., DavidsonB.L., SteinC.S.Identification of PDGFR as a receptor for AAV-5 transduction.Nat Med2003; 9: 1306–1312.
43.
WingenderG., GarbiN., SchumakB.Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO.Eur J Immunol2006; 36: 12–20.
44.
LinJ., ZhiY., MaysL., WilsonJ.M.Vaccines based on novel adeno-associated virus vectors elicit aberrant CD8+ T-cell responses in mice.J Virol2007; 81: 11840–11849.
45.
KimD., GambhiraR., KaranamB.Generation and characterization of a preventive and therapeutic HPV DNA vaccine.Vaccine2008; 26: 351–360.
